Ligands for oral delivery of peptides across the blood-brain-barrier
Peptides are short chains of amino acids linked by peptide bonds. Many peptides and proteins are limited by their poor enzymatic stability and permeability across the intestinal epithelial membranes and/or blood-brain barrier (BBB). Parenteral administration of these peptides is unfavorable because...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Murad Al Gailani [verfasserIn] Mengyang Liu [verfasserIn] Jingyuan Wen [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Acta Materia Medica - Compuscript Ltd, 2023, 1(2022), 1, Seite 106-123 |
|---|---|
| Übergeordnetes Werk: |
volume:1 ; year:2022 ; number:1 ; pages:106-123 |
| Links: |
|---|
| DOI / URN: |
10.15212/AMM-2021-0007 |
|---|
| Katalog-ID: |
DOAJ090725263 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ090725263 | ||
| 003 | DE-627 | ||
| 005 | 20240414090149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.15212/AMM-2021-0007 |2 doi | |
| 035 | |a (DE-627)DOAJ090725263 | ||
| 035 | |a (DE-599)DOAJf3d5c2d2e7864438a89baa7c32419e0d | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RS1-441 | |
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Murad Al Gailani |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ligands for oral delivery of peptides across the blood-brain-barrier |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Peptides are short chains of amino acids linked by peptide bonds. Many peptides and proteins are limited by their poor enzymatic stability and permeability across the intestinal epithelial membranes and/or blood-brain barrier (BBB). Parenteral administration of these peptides is unfavorable because of procedural complications and low patient compliance with treatments. Instead, oral delivery is the preferred route of administration because it allows for self-administration and has a high degree of patient acceptability and compliance. Oral delivery of these peptides poses a major challenge, because the peptide drug must overcome both the physical and biochemical barriers of the gastrointestinal tract and BBB. An oral drug delivery system is beneficial because it can protect peptide drugs against degradation and deliver them to the brain, where they exert their pharmacological actions. The use of active-targeting ligands and/or cell-penetrating peptides increases penetration and uptake across the BBB. This review focuses on the diverse combinations of drug delivery systems, active-targeting ligands, and cell-penetrating peptides used to deliver peptides to the brain. | ||
| 650 | 4 | |a niosomes | |
| 650 | 4 | |a blood-brain-barrier (bbb) | |
| 650 | 4 | |a brain | |
| 650 | 4 | |a liposomes | |
| 650 | 4 | |a nanoparticles | |
| 650 | 4 | |a ligands | |
| 650 | 4 | |a oral delivery | |
| 650 | 4 | |a peptides | |
| 653 | 0 | |a Pharmacy and materia medica | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Mengyang Liu |e verfasserin |4 aut | |
| 700 | 0 | |a Jingyuan Wen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Acta Materia Medica |d Compuscript Ltd, 2023 |g 1(2022), 1, Seite 106-123 |w (DE-627)DOAJ090670353 |x 27377946 |7 nnns |
| 773 | 1 | 8 | |g volume:1 |g year:2022 |g number:1 |g pages:106-123 |
| 856 | 4 | 0 | |u https://doi.org/10.15212/AMM-2021-0007 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/f3d5c2d2e7864438a89baa7c32419e0d |z kostenfrei |
| 856 | 4 | 0 | |u https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2021-0007 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2737-7946 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_90 | ||
| 951 | |a AR | ||
| 952 | |d 1 |j 2022 |e 1 |h 106-123 | ||
| author_variant |
m a g mag m l ml j w jw |
|---|---|
| matchkey_str |
article:27377946:2022----::iadfrrleieyfetdscoshb |
| hierarchy_sort_str |
2022 |
| callnumber-subject-code |
RS |
| publishDate |
2022 |
| allfields |
10.15212/AMM-2021-0007 doi (DE-627)DOAJ090725263 (DE-599)DOAJf3d5c2d2e7864438a89baa7c32419e0d DE-627 ger DE-627 rakwb eng RS1-441 RM1-950 Murad Al Gailani verfasserin aut Ligands for oral delivery of peptides across the blood-brain-barrier 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Peptides are short chains of amino acids linked by peptide bonds. Many peptides and proteins are limited by their poor enzymatic stability and permeability across the intestinal epithelial membranes and/or blood-brain barrier (BBB). Parenteral administration of these peptides is unfavorable because of procedural complications and low patient compliance with treatments. Instead, oral delivery is the preferred route of administration because it allows for self-administration and has a high degree of patient acceptability and compliance. Oral delivery of these peptides poses a major challenge, because the peptide drug must overcome both the physical and biochemical barriers of the gastrointestinal tract and BBB. An oral drug delivery system is beneficial because it can protect peptide drugs against degradation and deliver them to the brain, where they exert their pharmacological actions. The use of active-targeting ligands and/or cell-penetrating peptides increases penetration and uptake across the BBB. This review focuses on the diverse combinations of drug delivery systems, active-targeting ligands, and cell-penetrating peptides used to deliver peptides to the brain. niosomes blood-brain-barrier (bbb) brain liposomes nanoparticles ligands oral delivery peptides Pharmacy and materia medica Therapeutics. Pharmacology Mengyang Liu verfasserin aut Jingyuan Wen verfasserin aut In Acta Materia Medica Compuscript Ltd, 2023 1(2022), 1, Seite 106-123 (DE-627)DOAJ090670353 27377946 nnns volume:1 year:2022 number:1 pages:106-123 https://doi.org/10.15212/AMM-2021-0007 kostenfrei https://doaj.org/article/f3d5c2d2e7864438a89baa7c32419e0d kostenfrei https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2021-0007 kostenfrei https://doaj.org/toc/2737-7946 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_62 GBV_ILN_65 GBV_ILN_90 AR 1 2022 1 106-123 |
| spelling |
10.15212/AMM-2021-0007 doi (DE-627)DOAJ090725263 (DE-599)DOAJf3d5c2d2e7864438a89baa7c32419e0d DE-627 ger DE-627 rakwb eng RS1-441 RM1-950 Murad Al Gailani verfasserin aut Ligands for oral delivery of peptides across the blood-brain-barrier 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Peptides are short chains of amino acids linked by peptide bonds. Many peptides and proteins are limited by their poor enzymatic stability and permeability across the intestinal epithelial membranes and/or blood-brain barrier (BBB). Parenteral administration of these peptides is unfavorable because of procedural complications and low patient compliance with treatments. Instead, oral delivery is the preferred route of administration because it allows for self-administration and has a high degree of patient acceptability and compliance. Oral delivery of these peptides poses a major challenge, because the peptide drug must overcome both the physical and biochemical barriers of the gastrointestinal tract and BBB. An oral drug delivery system is beneficial because it can protect peptide drugs against degradation and deliver them to the brain, where they exert their pharmacological actions. The use of active-targeting ligands and/or cell-penetrating peptides increases penetration and uptake across the BBB. This review focuses on the diverse combinations of drug delivery systems, active-targeting ligands, and cell-penetrating peptides used to deliver peptides to the brain. niosomes blood-brain-barrier (bbb) brain liposomes nanoparticles ligands oral delivery peptides Pharmacy and materia medica Therapeutics. Pharmacology Mengyang Liu verfasserin aut Jingyuan Wen verfasserin aut In Acta Materia Medica Compuscript Ltd, 2023 1(2022), 1, Seite 106-123 (DE-627)DOAJ090670353 27377946 nnns volume:1 year:2022 number:1 pages:106-123 https://doi.org/10.15212/AMM-2021-0007 kostenfrei https://doaj.org/article/f3d5c2d2e7864438a89baa7c32419e0d kostenfrei https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2021-0007 kostenfrei https://doaj.org/toc/2737-7946 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_62 GBV_ILN_65 GBV_ILN_90 AR 1 2022 1 106-123 |
| allfields_unstemmed |
10.15212/AMM-2021-0007 doi (DE-627)DOAJ090725263 (DE-599)DOAJf3d5c2d2e7864438a89baa7c32419e0d DE-627 ger DE-627 rakwb eng RS1-441 RM1-950 Murad Al Gailani verfasserin aut Ligands for oral delivery of peptides across the blood-brain-barrier 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Peptides are short chains of amino acids linked by peptide bonds. Many peptides and proteins are limited by their poor enzymatic stability and permeability across the intestinal epithelial membranes and/or blood-brain barrier (BBB). Parenteral administration of these peptides is unfavorable because of procedural complications and low patient compliance with treatments. Instead, oral delivery is the preferred route of administration because it allows for self-administration and has a high degree of patient acceptability and compliance. Oral delivery of these peptides poses a major challenge, because the peptide drug must overcome both the physical and biochemical barriers of the gastrointestinal tract and BBB. An oral drug delivery system is beneficial because it can protect peptide drugs against degradation and deliver them to the brain, where they exert their pharmacological actions. The use of active-targeting ligands and/or cell-penetrating peptides increases penetration and uptake across the BBB. This review focuses on the diverse combinations of drug delivery systems, active-targeting ligands, and cell-penetrating peptides used to deliver peptides to the brain. niosomes blood-brain-barrier (bbb) brain liposomes nanoparticles ligands oral delivery peptides Pharmacy and materia medica Therapeutics. Pharmacology Mengyang Liu verfasserin aut Jingyuan Wen verfasserin aut In Acta Materia Medica Compuscript Ltd, 2023 1(2022), 1, Seite 106-123 (DE-627)DOAJ090670353 27377946 nnns volume:1 year:2022 number:1 pages:106-123 https://doi.org/10.15212/AMM-2021-0007 kostenfrei https://doaj.org/article/f3d5c2d2e7864438a89baa7c32419e0d kostenfrei https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2021-0007 kostenfrei https://doaj.org/toc/2737-7946 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_62 GBV_ILN_65 GBV_ILN_90 AR 1 2022 1 106-123 |
| allfieldsGer |
10.15212/AMM-2021-0007 doi (DE-627)DOAJ090725263 (DE-599)DOAJf3d5c2d2e7864438a89baa7c32419e0d DE-627 ger DE-627 rakwb eng RS1-441 RM1-950 Murad Al Gailani verfasserin aut Ligands for oral delivery of peptides across the blood-brain-barrier 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Peptides are short chains of amino acids linked by peptide bonds. Many peptides and proteins are limited by their poor enzymatic stability and permeability across the intestinal epithelial membranes and/or blood-brain barrier (BBB). Parenteral administration of these peptides is unfavorable because of procedural complications and low patient compliance with treatments. Instead, oral delivery is the preferred route of administration because it allows for self-administration and has a high degree of patient acceptability and compliance. Oral delivery of these peptides poses a major challenge, because the peptide drug must overcome both the physical and biochemical barriers of the gastrointestinal tract and BBB. An oral drug delivery system is beneficial because it can protect peptide drugs against degradation and deliver them to the brain, where they exert their pharmacological actions. The use of active-targeting ligands and/or cell-penetrating peptides increases penetration and uptake across the BBB. This review focuses on the diverse combinations of drug delivery systems, active-targeting ligands, and cell-penetrating peptides used to deliver peptides to the brain. niosomes blood-brain-barrier (bbb) brain liposomes nanoparticles ligands oral delivery peptides Pharmacy and materia medica Therapeutics. Pharmacology Mengyang Liu verfasserin aut Jingyuan Wen verfasserin aut In Acta Materia Medica Compuscript Ltd, 2023 1(2022), 1, Seite 106-123 (DE-627)DOAJ090670353 27377946 nnns volume:1 year:2022 number:1 pages:106-123 https://doi.org/10.15212/AMM-2021-0007 kostenfrei https://doaj.org/article/f3d5c2d2e7864438a89baa7c32419e0d kostenfrei https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2021-0007 kostenfrei https://doaj.org/toc/2737-7946 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_62 GBV_ILN_65 GBV_ILN_90 AR 1 2022 1 106-123 |
| allfieldsSound |
10.15212/AMM-2021-0007 doi (DE-627)DOAJ090725263 (DE-599)DOAJf3d5c2d2e7864438a89baa7c32419e0d DE-627 ger DE-627 rakwb eng RS1-441 RM1-950 Murad Al Gailani verfasserin aut Ligands for oral delivery of peptides across the blood-brain-barrier 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Peptides are short chains of amino acids linked by peptide bonds. Many peptides and proteins are limited by their poor enzymatic stability and permeability across the intestinal epithelial membranes and/or blood-brain barrier (BBB). Parenteral administration of these peptides is unfavorable because of procedural complications and low patient compliance with treatments. Instead, oral delivery is the preferred route of administration because it allows for self-administration and has a high degree of patient acceptability and compliance. Oral delivery of these peptides poses a major challenge, because the peptide drug must overcome both the physical and biochemical barriers of the gastrointestinal tract and BBB. An oral drug delivery system is beneficial because it can protect peptide drugs against degradation and deliver them to the brain, where they exert their pharmacological actions. The use of active-targeting ligands and/or cell-penetrating peptides increases penetration and uptake across the BBB. This review focuses on the diverse combinations of drug delivery systems, active-targeting ligands, and cell-penetrating peptides used to deliver peptides to the brain. niosomes blood-brain-barrier (bbb) brain liposomes nanoparticles ligands oral delivery peptides Pharmacy and materia medica Therapeutics. Pharmacology Mengyang Liu verfasserin aut Jingyuan Wen verfasserin aut In Acta Materia Medica Compuscript Ltd, 2023 1(2022), 1, Seite 106-123 (DE-627)DOAJ090670353 27377946 nnns volume:1 year:2022 number:1 pages:106-123 https://doi.org/10.15212/AMM-2021-0007 kostenfrei https://doaj.org/article/f3d5c2d2e7864438a89baa7c32419e0d kostenfrei https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2021-0007 kostenfrei https://doaj.org/toc/2737-7946 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_62 GBV_ILN_65 GBV_ILN_90 AR 1 2022 1 106-123 |
| language |
English |
| source |
In Acta Materia Medica 1(2022), 1, Seite 106-123 volume:1 year:2022 number:1 pages:106-123 |
| sourceStr |
In Acta Materia Medica 1(2022), 1, Seite 106-123 volume:1 year:2022 number:1 pages:106-123 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
niosomes blood-brain-barrier (bbb) brain liposomes nanoparticles ligands oral delivery peptides Pharmacy and materia medica Therapeutics. Pharmacology |
| isfreeaccess_bool |
true |
| container_title |
Acta Materia Medica |
| authorswithroles_txt_mv |
Murad Al Gailani @@aut@@ Mengyang Liu @@aut@@ Jingyuan Wen @@aut@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
DOAJ090670353 |
| id |
DOAJ090725263 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ090725263</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414090149.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240412s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.15212/AMM-2021-0007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ090725263</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf3d5c2d2e7864438a89baa7c32419e0d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Murad Al Gailani</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Ligands for oral delivery of peptides across the blood-brain-barrier</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Peptides are short chains of amino acids linked by peptide bonds. Many peptides and proteins are limited by their poor enzymatic stability and permeability across the intestinal epithelial membranes and/or blood-brain barrier (BBB). Parenteral administration of these peptides is unfavorable because of procedural complications and low patient compliance with treatments. Instead, oral delivery is the preferred route of administration because it allows for self-administration and has a high degree of patient acceptability and compliance. Oral delivery of these peptides poses a major challenge, because the peptide drug must overcome both the physical and biochemical barriers of the gastrointestinal tract and BBB. An oral drug delivery system is beneficial because it can protect peptide drugs against degradation and deliver them to the brain, where they exert their pharmacological actions. The use of active-targeting ligands and/or cell-penetrating peptides increases penetration and uptake across the BBB. This review focuses on the diverse combinations of drug delivery systems, active-targeting ligands, and cell-penetrating peptides used to deliver peptides to the brain.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">niosomes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">blood-brain-barrier (bbb)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">brain</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">liposomes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nanoparticles</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ligands</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">oral delivery</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">peptides</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mengyang Liu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jingyuan Wen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Acta Materia Medica</subfield><subfield code="d">Compuscript Ltd, 2023</subfield><subfield code="g">1(2022), 1, Seite 106-123</subfield><subfield code="w">(DE-627)DOAJ090670353</subfield><subfield code="x">27377946</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:106-123</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.15212/AMM-2021-0007</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f3d5c2d2e7864438a89baa7c32419e0d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2021-0007</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2737-7946</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="h">106-123</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Murad Al Gailani |
| spellingShingle |
Murad Al Gailani misc RS1-441 misc RM1-950 misc niosomes misc blood-brain-barrier (bbb) misc brain misc liposomes misc nanoparticles misc ligands misc oral delivery misc peptides misc Pharmacy and materia medica misc Therapeutics. Pharmacology Ligands for oral delivery of peptides across the blood-brain-barrier |
| authorStr |
Murad Al Gailani |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)DOAJ090670353 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RS1-441 |
| illustrated |
Not Illustrated |
| issn |
27377946 |
| topic_title |
RS1-441 RM1-950 Ligands for oral delivery of peptides across the blood-brain-barrier niosomes blood-brain-barrier (bbb) brain liposomes nanoparticles ligands oral delivery peptides |
| topic |
misc RS1-441 misc RM1-950 misc niosomes misc blood-brain-barrier (bbb) misc brain misc liposomes misc nanoparticles misc ligands misc oral delivery misc peptides misc Pharmacy and materia medica misc Therapeutics. Pharmacology |
| topic_unstemmed |
misc RS1-441 misc RM1-950 misc niosomes misc blood-brain-barrier (bbb) misc brain misc liposomes misc nanoparticles misc ligands misc oral delivery misc peptides misc Pharmacy and materia medica misc Therapeutics. Pharmacology |
| topic_browse |
misc RS1-441 misc RM1-950 misc niosomes misc blood-brain-barrier (bbb) misc brain misc liposomes misc nanoparticles misc ligands misc oral delivery misc peptides misc Pharmacy and materia medica misc Therapeutics. Pharmacology |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Acta Materia Medica |
| hierarchy_parent_id |
DOAJ090670353 |
| hierarchy_top_title |
Acta Materia Medica |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)DOAJ090670353 |
| title |
Ligands for oral delivery of peptides across the blood-brain-barrier |
| ctrlnum |
(DE-627)DOAJ090725263 (DE-599)DOAJf3d5c2d2e7864438a89baa7c32419e0d |
| title_full |
Ligands for oral delivery of peptides across the blood-brain-barrier |
| author_sort |
Murad Al Gailani |
| journal |
Acta Materia Medica |
| journalStr |
Acta Materia Medica |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
txt |
| container_start_page |
106 |
| author_browse |
Murad Al Gailani Mengyang Liu Jingyuan Wen |
| container_volume |
1 |
| class |
RS1-441 RM1-950 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Murad Al Gailani |
| doi_str_mv |
10.15212/AMM-2021-0007 |
| author2-role |
verfasserin |
| title_sort |
ligands for oral delivery of peptides across the blood-brain-barrier |
| callnumber |
RS1-441 |
| title_auth |
Ligands for oral delivery of peptides across the blood-brain-barrier |
| abstract |
Peptides are short chains of amino acids linked by peptide bonds. Many peptides and proteins are limited by their poor enzymatic stability and permeability across the intestinal epithelial membranes and/or blood-brain barrier (BBB). Parenteral administration of these peptides is unfavorable because of procedural complications and low patient compliance with treatments. Instead, oral delivery is the preferred route of administration because it allows for self-administration and has a high degree of patient acceptability and compliance. Oral delivery of these peptides poses a major challenge, because the peptide drug must overcome both the physical and biochemical barriers of the gastrointestinal tract and BBB. An oral drug delivery system is beneficial because it can protect peptide drugs against degradation and deliver them to the brain, where they exert their pharmacological actions. The use of active-targeting ligands and/or cell-penetrating peptides increases penetration and uptake across the BBB. This review focuses on the diverse combinations of drug delivery systems, active-targeting ligands, and cell-penetrating peptides used to deliver peptides to the brain. |
| abstractGer |
Peptides are short chains of amino acids linked by peptide bonds. Many peptides and proteins are limited by their poor enzymatic stability and permeability across the intestinal epithelial membranes and/or blood-brain barrier (BBB). Parenteral administration of these peptides is unfavorable because of procedural complications and low patient compliance with treatments. Instead, oral delivery is the preferred route of administration because it allows for self-administration and has a high degree of patient acceptability and compliance. Oral delivery of these peptides poses a major challenge, because the peptide drug must overcome both the physical and biochemical barriers of the gastrointestinal tract and BBB. An oral drug delivery system is beneficial because it can protect peptide drugs against degradation and deliver them to the brain, where they exert their pharmacological actions. The use of active-targeting ligands and/or cell-penetrating peptides increases penetration and uptake across the BBB. This review focuses on the diverse combinations of drug delivery systems, active-targeting ligands, and cell-penetrating peptides used to deliver peptides to the brain. |
| abstract_unstemmed |
Peptides are short chains of amino acids linked by peptide bonds. Many peptides and proteins are limited by their poor enzymatic stability and permeability across the intestinal epithelial membranes and/or blood-brain barrier (BBB). Parenteral administration of these peptides is unfavorable because of procedural complications and low patient compliance with treatments. Instead, oral delivery is the preferred route of administration because it allows for self-administration and has a high degree of patient acceptability and compliance. Oral delivery of these peptides poses a major challenge, because the peptide drug must overcome both the physical and biochemical barriers of the gastrointestinal tract and BBB. An oral drug delivery system is beneficial because it can protect peptide drugs against degradation and deliver them to the brain, where they exert their pharmacological actions. The use of active-targeting ligands and/or cell-penetrating peptides increases penetration and uptake across the BBB. This review focuses on the diverse combinations of drug delivery systems, active-targeting ligands, and cell-penetrating peptides used to deliver peptides to the brain. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_62 GBV_ILN_65 GBV_ILN_90 |
| container_issue |
1 |
| title_short |
Ligands for oral delivery of peptides across the blood-brain-barrier |
| url |
https://doi.org/10.15212/AMM-2021-0007 https://doaj.org/article/f3d5c2d2e7864438a89baa7c32419e0d https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2021-0007 https://doaj.org/toc/2737-7946 |
| remote_bool |
true |
| author2 |
Mengyang Liu Jingyuan Wen |
| author2Str |
Mengyang Liu Jingyuan Wen |
| ppnlink |
DOAJ090670353 |
| callnumber-subject |
RS - Pharmacy |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.15212/AMM-2021-0007 |
| callnumber-a |
RS1-441 |
| up_date |
2024-07-03T16:22:02.457Z |
| _version_ |
1803575594804314112 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ090725263</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414090149.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240412s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.15212/AMM-2021-0007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ090725263</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf3d5c2d2e7864438a89baa7c32419e0d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Murad Al Gailani</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Ligands for oral delivery of peptides across the blood-brain-barrier</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Peptides are short chains of amino acids linked by peptide bonds. Many peptides and proteins are limited by their poor enzymatic stability and permeability across the intestinal epithelial membranes and/or blood-brain barrier (BBB). Parenteral administration of these peptides is unfavorable because of procedural complications and low patient compliance with treatments. Instead, oral delivery is the preferred route of administration because it allows for self-administration and has a high degree of patient acceptability and compliance. Oral delivery of these peptides poses a major challenge, because the peptide drug must overcome both the physical and biochemical barriers of the gastrointestinal tract and BBB. An oral drug delivery system is beneficial because it can protect peptide drugs against degradation and deliver them to the brain, where they exert their pharmacological actions. The use of active-targeting ligands and/or cell-penetrating peptides increases penetration and uptake across the BBB. This review focuses on the diverse combinations of drug delivery systems, active-targeting ligands, and cell-penetrating peptides used to deliver peptides to the brain.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">niosomes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">blood-brain-barrier (bbb)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">brain</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">liposomes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nanoparticles</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ligands</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">oral delivery</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">peptides</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mengyang Liu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jingyuan Wen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Acta Materia Medica</subfield><subfield code="d">Compuscript Ltd, 2023</subfield><subfield code="g">1(2022), 1, Seite 106-123</subfield><subfield code="w">(DE-627)DOAJ090670353</subfield><subfield code="x">27377946</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:106-123</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.15212/AMM-2021-0007</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f3d5c2d2e7864438a89baa7c32419e0d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2021-0007</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2737-7946</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="h">106-123</subfield></datafield></record></collection>
|
| score |
7.401041 |